BioInvent (BOVNF) Appoints Head Of Clinical Development

BioInvent International AB (STO:BINV) today announced that Anna Wickenberg has been appointed as Vice President Clinical Development, responsible for the clinical development of BioInvent's drug development projects. She will be part of the Management group and reports to the CEO.

Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.